AstraZeneca has announced a $50 billion investment in its US operations over the next five years. The British-Swedish pharmaceutical company plans to expand its research, manufacturing, and supply capabilities to meet rising demand under the new affordability scheme.
“This large-scale investment will strengthen domestic production and reduce the country’s dependence on imported drugs,” the company stated.
As part of the initiative, AstraZeneca is expected to collaborate with the US government to develop and distribute low-cost medicines through TrumpRx.gov. The TrumpRx platform will allow citizens to buy approved prescription drugs directly through a government-backed website, eliminating intermediaries and lowering costs. The portal is built around a new pricing model that promises greater transparency and fairer rates for essential medicines. Officials said it will include a broad range of widely used drugs, including treatments for chronic conditions such as diabetes, hypertension, and cancer.
Under new supply arrangements with major pharmaceutical companies, some of these medicines could be offered at “near zero” cost.
Also Read
